Search - tctmd.com

Displaying 1 - 20 of 100

Sort: Relevancy | Date

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

February 02, 2026

FDA Approves Aficamten for Obstructive HCM

News Daily News

FDA Approves Aficamten for Obstructive HCM

December 29, 2025

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

December 15, 2025

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

News Daily News

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

October 02, 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

News Conference News HFSA 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Yael L. Maxwell

October 01, 2025

Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients

News Daily News

Transthyretin Cardiac Amyloidosis a Common Cause of HF in Older Black Patients

September 12, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

July 14, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

April 15, 2025

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

March 21, 2025

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

News Daily News

Sotagliflozin Reduces Ischemic Risk in SCORED Analysis

Yael L. Maxwell

February 25, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

News Daily News

Vascular Disease History Need Not Preclude Aspirin Withdrawal After HeartMate 3

Yael L. Maxwell

January 15, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.